Welcome to the Right Decision Service (RDS) newsletter for June 2024.
Hopefully you all received the notification on Friday 28th June about the worldwide security vulnerability relating to use of code from the Polyfill.io code library – typically used to enable use of functionality in older browsers and operating systems. This vulnerability has now been addressed within RDS. Thanks to Tactuum for their prompt action on this.
This incident served as a useful reminder about the importance of making sure all devices and desktop/laptop computers have up to date anti-malware installed.
The most recent information is that final fixes and developments will take place during July, with a view to user testing taking place in August 2024.
We will be running the six-monthly usage statistics reports for all RDS toolkits during July. Please contact his.decisionsupport@nhs.scot if you would like to receive the usage report for your toolkit(s).
The Scottish Palliative Care Group is carrying out a value and impact survey of the national Palliative Care Guidelines toolkit on RDS. We would appreciate your help in circulating this survey, available at https://rightdecisions.scot.nhs.uk/scottish-palliative-care-guidelines/evaluation-survey/ /
The Palliative Care Guidelines toolkit is using an adapted version of a generic impact evaluation form which the RDS team now encourages all toolkit owners to apply 6-12 months after launch of their toolkit. Please contact ann.wales3@nhs.scot if you would like to find out more.
The RDS Learning working group is in the final stages of developing and uploading new learning resources including:
We have also drafted a communication and training plan to support implementation of the redesigned RDS. The plan aims to reach both end-users and editors, who will benefit from new features such as the archiving and version control functionality.
4.1 Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:
To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)
Remember that you can also organise 1-1 training sessions with Olivia on running Google Analytics reports if you want to look at data more frequently than the six-monthly reports.
The following RDS toolkits are now live:
The following toolkits are due to go live imminently:
Some of the toolkits the RDS team is currently working on:
Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.
HIS is working with the Scottish Library and Information Council and the ALLIANCE to implement the second phase of the Collective Force for Health and Wellbeing Action Plan. This plan aims to strengthen the role of public, health and school libraries in empowering people to use digital tools and health information for self-management and choices about health and wellbeing. A key element of this new phase is supporting public libraries to promote the RDS citizen-facing apps for health and wellbeing.
We held a webinar on 28th June about the implementation challenge for health and wellbeing apps for citizens. This included an overview of the evidence base around implementation, the critical importance of health literacy skills, and the early findings from tests of change of implementing the Being a partner in my care app. Please contact his.decisionsupport@nhs.scot if you would like a copy of the slides or access to the recording of this webinar (NHS staff only.)
If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.
With kind regards
Right Decision Service team
Healthcare Improvement Scotland
27/04/23 - Solriamfetol film coated tablets 75mg, 150mg, SMC2439 indication, added.
CNS stimulant medication (methylphenidate, lisdexamfetamine) is only indicated for the treatment of attention deficit hyperactivity disorder (ADHD) under specialist supervision. Initiation, stabilisation and ongoing supervision are provided by the relevant specialist. Unacceptable side-effects or a poor response to first-line treatment can be discussed with the specialist. When response to stimulants is inadequate or when stimulants are unsuitable or not tolerated, use of the non-stimulant atomoxetine or guanfacine may be considered.
For information on prescribing in ADHD and the characteristics and release profiles of immediate and modified-release formulations of methylphenidate, refer to SIGN guidance (www.sign.ac.uk) and to the shared-care protocol. In a small minority of patients response to methylphenidate therapy may differ if the formulation changes; brand name prescribing may be required as per BNF advice.
MHRA advice: Atomoxetine (Strattera▼): increases in blood pressure and heart rate (December 2014) (www.gov.uk).
Capsules 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg (s)
Oral solution 4mg/mL (s)
Modified release tablets 1mg, 2mg, 3mg, 4mg (s)
Capsules (CD schedule 2) 20mg, 30mg, 40mg, 50mg, 60mg, 70mg (s)
MHRA advice: Methylphenidate long-acting (modified-release) preparations: caution if switching between products due to differences in formulations (September 2022) (www.gov.uk).
Tablets (CD schedule 2) 5mg, 10mg, 20mg (s)
Modified release tablets (Xenidate XL®) (CD schedule 2) 18mg, 27mg, 36mg, 54mg (s)
Modified release capsules (Equasym XL®) (CD schedule 2) 10mg, 20mg, 30mg (s)
Modified release capsules (MedikinetXL®) (CD schedule 2) 5mg, 10mg, 20mg, 30mg, 40mg (s)
To be used second line after the use of modafinil with the goal of improving wakefulness in patients with narcolepsy who did not respond to or did not tolerate modafinil.
Film-coated tablets 75mg, 150mg (specialist recommendation only)
See SMC advice 2439.
TAM (Treatments and Medicines) NHS Highland